).
Results:
Nine studies in which immediate reactions to GBCA were recorded from a total of 716 978 administrations of GBCA met the criteria for inclusion and exclusion. The overall and severe rates of GBCA allergic-like adverse events were 9.2 and 0.52 per 10 000 administrations, respectively: 81% (539 of 662) were mild, 13% (86 of 662) were moderate, and 6% (37 of 662) were severe reactions. The nonionic linear chelate gadodiamide had the lowest rate of reactions, at 1. 
Conclusion:
These data show the lowest rate of immediate allergic adverse events with use of the nonionic linear GBCA gadodiamide in comparison with those of ionic linear or nonionic macrocyclic GBCAs. A higher rate of immediate allergic adverse events was associated with ionicity, protein binding, and macrocyclic structure.
the topic from the same institutions. Finally, we excluded articles in which the authors did not use the American College of Radiology (ACR) Manual on Contrast Media Classification system for dividing acute reactions into three categories (mild, moderate, and severe) (17) (18) (19) (20) . Since the ACR Manual on Contrast Media evolved during the past 10 years, with a separation of allergic-like and physiologic reactions in the more recent versions (19, 20) , we contacted authors of articles for further information, when necessary, to exclude physiologic reactions (as defined in the ACR Manual on Contrast Media pages 103-104 [20] ) from the data on mild, moderate, and severe allergic-like reactions. We assessed risk of bias in the nine final studies by using A Cochrane Risk of Bias Assessment Tool for Non-Randomized Studies of Interventions, or ACROBAT-NRSI (21) .
Data Extraction
Two authors (B.A.H.and Z.F.) independently read each article that met inclusion and exclusion criteria and extracted the number of administrations; the numbers of mild, moderate, and severe reactions; and the number of deaths for each GBCA. For articles in which both immediate and delayed reactions were large case series are combined. The purpose of this systematic review and meta-analysis was to determine if there are differences in rates of immediate allergic events among types of GBCAs.
Materials and Methods

Search Strategy
This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, or PRISMA (16) . A search of the PubMed and Google Scholar databases for all published studies through February 2017 was conducted independently by two radiology research fellows (B.A.H. and Z.F., with 10 and 3 years of experience, respectively). The following key words were used: "GBCA" or "gadolinium" combined with "adverse effect," "adverse event," or "allergic reaction." Reference lists of the retrieved articles were screened, and additional manual citation searching was performed for each article that met inclusion criteria, with removal of duplicate articles. There were no language limitations. Then, titles and abstracts were reviewed, and comments, letters, reviews, and articles in which rates of immediate adverse reactions to specific GBCAs were not reported were excluded. On the basis of full-text review of the remaining articles, six studies were excluded because reactions to GBCAs were reported generically instead of being attributed to a specific GBCA. Two articles were excluded because they overlapped with subsequent, updated articles on 
Implication for Patient Care
n When patients with glomerular filtration rates greater than 30 mL/min per 1.73 m 2 and for whom there is clinical concern for allergic reactions require contrast material-enhanced MR imaging, it is reasonable to consider the issues of ionicity, protein binding, and macrocyclic versus linear chelate structure when selecting a GBCA.
T he extraordinarily low incidence of adverse reactions to gadoliniumbased contrast agents (GBCAs) has frustrated efforts to compare their relative safety, because hundreds of thousands of administrations may be necessary to detect differences at these low rates. Ionic and nonionic iodinebased contrast agents are known to have different immediate reaction rates. GBCA adverse reactions occur less frequently but may also have differences related to chemical structure, ionicity, and affinity for serum proteins (1) (2) (3) (4) (5) .
Data on immediate reactions to GBCAs have been reported in large case series (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) Note.-Data in parentheses are 95% confidence intervals (CIs). Numbers in parentheses in row headings are reference numbers.
* Blood pool distribution and hepatobiliary excretion were derived from transiently binding serum albumin or other proteins (protein-binding agents) (28) .
reported, data on the delayed reactions were excluded. All discrepancies in the data extractions between the two observers were resolved in consensus with a third reviewer (M.R.P., with 30 years of radiology research experience).
Classification of Adverse Events
All selected articles included use of the ACR Manual on Contrast Media system for classification of acute reactions as mild, moderate, or severe (17) (18) (19) (20) . Mild allergic-like reactions were self-limited, without evidence of progression and included limited urticaria, pruritus, limited cutaneous edema, limited itching or "scratchy" throat, nasal congestion, sneezing, conjunctivitis, and rhinorrhea. Moderate reactions were more pronounced, commonly required medical treatment, and included diffuse urticaria and/or puritis, diffuse erythema with stable vital signs, facial edema without dyspnea, throat tightness or hoarseness without dyspnea, wheezing, and mild bronchospasm without hypoxia. Severe reactions were potentially life-threatening, with risk of permanent morbidity or death if not treated appropriately, and included diffuse edema or facial edema with dyspnea, diffuse erythema with hypotension, laryngeal edema with stridor and/or hypoxia, wheezing and/ or bronchospasm, substantial hypoxia, and anaphylactic shock (17) (18) (19) (20) .
Classification of GBCA Type
GBCAs were grouped according to their chemical structure and properties (Table 1 ) (22) (23) (24) (25) (26) (27) (28) . Each GBCA was either macrocyclic (gadoterate, gadobutrol, and gadoteridol) or linear (all of the rest). GBCAs also were grouped according to ionicity. There were data on a single nonionic linear GBCA (gadodiamide), which was compared with four ionic linear GBCAs to assess the effect of ionicity. Three of the ionic linear GBCAs had moieties that transiently bound serum proteins (eg, albumin) that conferred high relaxivity and blood pool distribution (gadofosveset), high relaxivity and 50% hepatobiliary excretion (gadoxetate), and high relaxivity and 4% hepatobiliary excretion (gadobenate Note.-Dates in parentheses indicate the time period during which the study was performed. Numbers in brackets are the reference numbers for each study.
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Statistical Methods
The mild, moderate, severe or fatal, and overall reaction rates; severe or fatal reaction rates; and moderate or severe or fatal reaction rates were compared among different GBCA groups as we have described. For each comparison, we only used data from the articles in which both types of GBCAs were investigated. Relative risk was estimated by using the Mantel-Haenszel type method both allergic and physiologic reactions. In one of these (9), all physiologic reactions could be excluded without contacting the authors. In the remaining five articles (2,11-13,15) in which both allergic-like and physiologic reactions were reported, authors were contacted for clarification. In this way, 321 physiologic reactions were eliminated, leaving 662 allergic-like reactions ( Table 2 ). The overall rate of patients who had immediate allergic-like reactions was 9.2 per 10 000 administrations and the overall rate of severe immediate allergic-like reactions was 0.52 per 10 000 administrations. Breakdowns according to individual GBCA appear in Table 1 and Figure 2 , and according to chemical structure in Tables 3 and 4 . In this cohort, 81% (539 of 662) of reactions were mild, 13% (86 of 662) were moderate, and 6% (37 of 662) were severe.
The nonionic linear GBCA, gadodiamide, had the lowest overall rate of immediate adverse reactions, at 1.5 per 10 000 administrations, which was significantly less than that for linear ionic GBCAs, at 8.3 per 10 000 administrations (relative risk, 0.19; P , .00001) (Fig 3a) and less than that for nonionic macrocyclic agents, at 16 per 10 000 administrations (relative risk, 0.12; P , .001) (Fig 3d) . These data and CIs are included in Table 3 .
The nonionic linear GBCA also had the lowest rate of moderate and severe of Rothman and Boice (29) , and an x 2 test was performed with the hypothesis that relative risk would equal 1. We considered a type I error of .05 as indicative of a significant difference (P , .05). We also conducted additional meta-analyses by comparing overall reaction rates between the GBCA with the lowest reaction rate and each of the other agents. For all meta-analyses, we performed heterogeneity assessment by using both the Cochran Q and I 2 statistics. A moderate heterogeneity among studies was determined as a P value of the Cochran Q less than 0.1 and an I 2 greater than 50%, and severe heterogeneity was considered with a P value of the Cochran Q less than .05 or an I 2 greater than 75%. Random effects were added when severe heterogeneity was detected (30, 31) . For all statistical calculations, we used software (StatsDirect statistical software version 3.0.198; StatsDirect, Altrincham, England).
Results
Nine articles met the criteria and included a total of 716 978 GBCA administrations ( Table 2, Fig 1) , with 983 administrations reported to have resulted in immediate adverse reactions. Three articles reported only allergic-like reactions (7,10,14) . The other six articles reported
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Behzadi et al (Fig 3 continues) . (Fig 3d) . The comparison of ionic linear GBCA without protein binding (gadopentetate dimeglumine) to ionic macrocyclic GBCA (gadoterate) involved a smaller number of injections and did not show a significant difference.
4, Fig 4a
(including fatal) adverse reactions, at 0.38, compared with linear ionic GBCAs, at 1.9 per 10 000 administrations (relative risk, 0.2; P = .017) (Table
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Behzadi et al We also did not observe a difference between ionic macrocyclic and nonionic macrocyclic GBCAs. All GBCAs with protein binding (gadoxetate, gadofosveset, and gadobenate) were linear ionic GBCAs. Protein binding was associated with a greater rate of reactions, at 17 (95% CI: 15, 20) per 10 000 injections compared with gadopentetate dimeglumine, the one ionic linear agent without protein binding, at 5.2 (95% CI: 4.5, 6.0) per 10 000 injections (relative risk, 3.1 [95% CI: 2.4, 3.8]; P , .0001) (Fig  3b) . Moreover, the rate of severe or fatal reactions was greater for protein binding (gadoxetate, gadofosveset, and gadobenate) linear ionic GBCAs, at 1.23 (95% CI: 0.7, 1.9) per 10 000 injections, compared with a non-protein-binding linear ionic GBCA (gadopentetate dimeglumine), at 0.21 (95% CI: 0.09, 0.04) per 10 000 injections (relative risk, 6.3 [95% CI: 2, 20]; P = .0021) (Figs 3d, 4b ).
There were two deaths caused by severe reactions to GBCAs, with a rate of 2.7 per 1 million administrations. An ionic GBCA with protein binding, gadobenate dimeglumine caused one death, and the other death was related to a macrocyclic GBCA, gadobutrol.
By using ACROBAT-NRSI (21), we found a moderate risk of bias due to missing data in six articles. In two articles (12, 14) , data were missing on the type of GBCA that induced reactions. In five articles (2, (11) (12) (13) 15) , data on physiologic and allergic reactions were initially pooled. Authors were contacted to resolve these biases. In one article (10), investigators reported data collection partially funded by industry. None of the other studies reported industry agreements related to the study, but eight of 67 authors reported industry agreements unrelated to the study. In seven articles, moderate bias due to confounding was present (eg, use of gadoxetate for liver MR imaging and different GBCAs for other indications). All nine studies had a low risk of bias in selection of cases into the study in the reported results, in measurement of outcomes, and finally a moderate risk of overall bias (Table 5) .
Behzadi et al (Fig 4 continues) .
Discussion
The extraordinarily low rate of immediate reactions to GBCAs and the rare incidence of fatal reactions has led to a generalization that all GBCAs are safe, especially compared with iodine-based contrast media (1) (2) (3) (4) (5) . Differences in reaction rates between GBCAs have been hypothesized but are difficult to prove due to the large number of patients needed to show statistically significant differences for such rare events (2, 7, (9) (10) (11) (12) (13) (14) (15) 32) . These data combined from nine well-designed studies (2, 7, (9) (10) (11) (12) (13) (14) (15) including 716 978 GBCA administrations show a higher rate of reactions associated with the properties of ionicity, protein binding, and cyclic structure. Ionic agents automatically separate into fragments, one positively charged and one negatively charged when they are injected into the blood stream, which doubles the number of particles in solution, doubling the osmolality and raising the viscosity, which may contribute to a higher reaction rate (33) (34) (35) . Thus, it is not surprising that the GBCA with the lowest rate of immediate allergic-like reactions was nonionic, and this property is well established as conferring a lower rate of reactions for iodine-based contrast agents (1, (36) (37) (38) (39) (40) (41) (42) . No effect of ionicity was observed for macrocyclic agents, although there are fewer data on macrocyclic GBCAs.
The favorable low reaction rate for nonionic linear GBCAs stands in contrast to their worrisome lower kinetic stability, which is thought to increase the risk of nephrogenic systemic fibrosis and gadolinium retention in the brain (22, (43) (44) (45) . Because risk of development of nephrogenic systemic fibrosis can be decreased by screening renal function before administration, nonionic linear agents may be considered for patients with normal renal function who are at increased risk of allergic reactions. This may include patients with asthma, severe allergies, or a history of prior reaction to other GBCAs. It may also be considered at centers that lack an immediately available code team to help treat severe reactions (eg, outpatient imaging centers), which can be EVIDENCE-BASED PRACTICE: Immediate Allergic Reactions to Gadolinium-based Contrast Agents Behzadi et al Table 5 Risk of Bias in the Included Studies Protein binding may confer the favorable qualities of higher GBCA relaxivity, hepatobiliary excretion, or sequestration within the blood pool (28) . Our observation of a higher rate of reactions for GBCAs with protein binding is also consistent with those of prior reports (46) .
Macrocyclic GBCAs had a greater rate of reactions compared with linear GBCAs, which was confirmed in a comparison of nonionic linear to nonionic macrocyclic GBCAs that was controlled for ionicity and protein-binding effects. This greater rate of allergiclike reactions must be considered with other aspects of safety including the favorable stability of macrocyclic agents that reduces risk of nephrogenic systemic fibrosis and gadolinium retention in the brain (43, 47, 48 ). An overall assessment of safety should not focus on a single GBCA property.
The two deaths reported in these nine publications correspond to a rate of 2.8 per 1 million administrations. Both deaths involved GBCAs with factors contributing to higher risk (2, 7) . Gadobenate is ionic and protein binding. Gadobutrol is macrocyclic. It is also important to consider that death due to an adverse reaction is a multifactorial event. It depends on the skills of the hospital staff in differentiating the symptoms of anaphylaxis from other differential diagnoses such as a vasovagal reaction or panic attack and in responding quickly before the reaction becomes life threatening (6, (49) (50) (51) (52) (53) (54) . The use of power injection may be a risk factor if it delays recognition and treatment of reactions. In at least one of these deaths, the patient received GBCA by means of power injection (2) , which contributed to a delay in diagnosis. Data on the method of injection for the other death were not available (7). When a power injector is used, the
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Behzadi et al close-proximity patient monitoring that automatically occurs with hand injections should not be allowed to lapse. Limitations of this meta-analysis included the retrospective analysis of data, which may have created a selection bias, and a dependence on meticulous record keeping for data accuracy. It was not possible to control for temporal biases, such as the Weber effect (10,55), because data on when each GBCA was used at each institution were not available. However, combining data from countries with different GBCA introduction dates (Korea, Japan, European countries, and the United States) with data collections spanning from 2000 to 2016 was expected to minimize temporal biases that might have been present.
Not all of the GBCAs were used by all of the authors, so differences in how each center reported events could have biased the results. We mitigated this risk by requiring that all articles involved the use of the ACR classification system for contrast material reactions, and we contacted authors to eliminate physiologic reactions. Eliminating physiologic reactions reduced heterogeneity. The limitation of study heterogeneity was also mitigated by using a random effects model when Cochran heterogeneity was high. Only one comparison required use of the random effects model due to high heterogeneity, and when we also used a fixed effects model for that comparison, the significance did not change. There was a variation in the number of subjects per study, ranging from 10 608 to 194 400, which could have overweighted the effect of larger studies. Finally, in spite of the large number of GBCA administrations, the very low incidence of moderate and severe reactions limited the statistical power for their evaluation.
In conclusion, by combining data from nine studies of immediate reactions to GBCA we showed that protein binding, macrocyclic structure, and ionicity are associated with higher rates of allergic-like adverse events. 
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